STRYKER

2017 Proxy Statement

Issue link: http://catalog.e-digitaleditions.com/i/801297

Contents of this Issue

Navigation

Page 20 of 69

17 Mr. Scannell — Group President, MedSurg and Neurotechnology 2016 Threshold 2016 Target Threshold as Percentage Change Over 2015 Actual Potential Payment as Percentage of Total Target Bonus (%) Target as Percentage Change Over 2015 Actual Potential Payment as Percentage of Total Target Bonus (%) Core Bonus Potential (1) : Operating income - group 4.9% 10 16.6% 20 Operating income - consolidated -2.1% 10 8.8% 20 Sales -1.2% 20 6.8% 40 Functional goal (2) — 0 — 20 40 100 Overachievement Bonus Potential (1) : Operating income - group 16.6% 0 23.6% 25 Operating income - consolidated 8.8% 0 13.1% 25 Sales 6.8% 0 11.1% 25 Diluted net earnings per share 9.4% 0 14.8% 25 0 100 ______________ (1) Goals are specific to the MedSurg and Neurotechnology Group reporting to Mr. Scannell, except the goals related to operating income - consolidated and diluted net earnings per share, which are total Company goals. (2) Qualitative assessment of his contributions to the execution of the Company's cost transformation initiative and deployment of the enterprise resource planning platform and accelerating growth while driving improved execution, capabilities and talent in Japan and Latin America markets. Mr. Floyd — Group President, Orthopaedics 2016 Threshold 2016 Target Threshold as Percentage Change Over 2015 Actual Potential Payment as Percentage of Total Target Bonus (%) Target as Percentage Change Over 2015 Actual Potential Payment as Percentage of Total Target Bonus (%) Core Bonus Potential (1) : Operating income - group -0.1% 10 11.0% 20 Operating income - consolidated -2.1% 10 8.8% 20 Sales -2.6% 20 5.3% 40 Functional goal (2) — 0 — 20 40 100 Overachievement Bonus Potential (1) : Operating income - group 11.0% 0 17.7% 25 Operating income - consolidated 8.8% 0 13.1% 25 Sales 5.3% 0 9.6% 25 Diluted net earnings per share 9.4% 0 14.8% 25 0 100 ______________ (1) Goals are specific to the Orthopaedics Group reporting to Mr. Floyd, except the goals related to operating income - consolidated and diluted net earnings per share, which are total Company goals. (2) Qualitative assessment of his contributions to the execution of the Company's cost transformation initiative and deployment of the enterprise resource planning platform and accelerating growth while driving improved execution, capabilities and talent in Asia and South Pacific markets.

Articles in this issue

view archives of STRYKER - 2017 Proxy Statement